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Results

Abstract
Chlamydia pneumoniae infection may be a trigger for the pathology observed in sporadic lateonset Alzheimer’s disease as a function of initiating neuroinflammation following entry of the
organism into the brain. We have hypothesized that one entry mechanism may be by bloodborne infected monocytes trafficking the infection into the brain. This study focuses on
infection of monocytes in vitro followed by analysis using immunofluorescence labeling and
RT-PCR-microarray techniques. The microarrays utilized consisted of an Alzheimer’s disease
pathway array and an innate and adaptive immunity array from SAbiosciences. Analysis by
real time PCR for both gene arrays was performed on uninfected and C. pneumoniae-infected THP1 monocytes at 48 hr post-infection. In addition, we analyzed innate and adaptive
immunity gene regulation changes following treatment of infected cells with a unique peptide, acALY18, derived from the endogenously expressed endoplasmic reticulum protein
TRPC1. The peptide appears to stimulate the innate immune system through activation of
the inflammasome. C. pneumoniae prominently infected THP1 monocytes at 24-48hr.
Numerous large inclusions were identified using specific chlamydial monoclonal antibodies.
Monocyte gene expression changes induced by infection with C. pneumoniae revealed significant up-regulation of 45 genes in the Alzheimer’s disease pathway. These included genes
involved in: b-amyloid processing and clearance, apoptosis, proteases and protein kinases,
and lipid metabolism. In contrast, infection resulted in significant changes in 30 genes governing innate and adaptive immunity including those for: the inflammatory response, host
defense against bacteria, cytokines, chemokines, and an antibacterial humoral response.
Intriguingly, following incubation of C. pneumoniae-infected cells with the acALY18 peptide
(25-50nM) at 24hr post-infection, there was significant clearance of the organism from the
monocytes as well as up-regulation of 38 genes. Our data suggest that C. pneumoniae
infection of monocytes has a profound effect on gene regulation for both innate and adaptive immunity and for Alzheimer’s disease. Stimulating the innate immune response using the
novel peptide, acALY18, promotes clearance of C. pneumoniae from infected monocytes;
thereby implicating the inflammasome as a key component in eradicating this infection.

Introduction
Infection with the respiratory obligate intracellular bacterium Chlamydia pneumoniae has
been shown to be involved in numerous human respiratory and non-respiratory diseases
including: community-acquired pneumonia and bronchitis (1), atherosclerosis and heart
disease (2; 3), and late-onset Alzheimer’s disease (4;5). C. pneumoniae gains access to the
circulation upon infection of monocytes, and potentially of lymphocytes (6;7). Chronic
persistence of C pneumoniae in circulating monocytes is likely, and may facilitate systemic
infection (8) through transfer of C. pneumoniae between infected monocytes and peripheral endothelial cells (9). Our laboratory has evidence that the monocyte is one key cell type
that may carry C. pneumoniae into the CNS (10; 11), and may implicate C. pneumoniae as
a major risk factor in the development of late-onset Alzheimer’s disease (for review see 12).
Impacting this infection with a therapeutic regimen may diminish the potential for infection in the CNS as well as elsewhere in the body. Antibiotics may be used in combating this
type of infection; however, an antibiotic regimen would not necessarily be prudent given
issues of antibiotic penetration to different anatomical sites, efficacy against chronic/persistent organisms and driving organisms into a persistent state, antibiotic resistance, and the
potential for the development of super-infections. Therefore, we are studying an alternative
method of combating infection by inducing the innate immune system to better respond
and eradicate this type of infection. Specifically, we are using a recently discovered lipopeptide (acALY-18) derived from the endogenous endoplasmic reticulum TRPC1 protein that
has been found to activate the innate immune response in fibroblasts and keratinocytes
(13). Our preliminary data suggest that this lipopeptide activates C. pneumoniae-infected
monocytes resulting in heightened clearance of the organism when compared to untreated
infected cells. Therefore the lipopeptide (acALY-18) may be a viable candidate for treating
C. pneumoniae infections in Alzheimer’s disease.
acALY-18 has been determined to have identical sequence homology to the internal
sequence of amino acids at positions 558-574 in the transient receptor potential channelrelated protein 1 (TRPC1) (13). No significant homology with other known proteins or
peptides has been noted. The TRPC family of proteins belongs to the TRP superfamily of
non-voltage-gated cation channel proteins of which at least seven TRPC family members
have been described in mammals (14). Members of the TRPC family, including TRPC1,
appear to be conserved within the animal kingdom and the trp gene family also appears to
be expressed in a wide variety of tissues and cell types including immune cells (for review
see 15). The topology of TRPC1 has been deduced (16) and the amino acid sequence comprising the acALY-18 peptide appears to reside in the extracellular region between the sixth
and seventh membrane spanning units. Sequence homology of this region of TRPC1 with
the other members of the TRPC family is relatively low (~30%) as compared to ~80% for
the N-terminal sequence (14).
The function of acALY-18 appears to involve the intracellular induction of specific
cytokines/chemokines and this may be independent of activation through toll-like receptors. The induction appears to activate the innate immune response by activating the
inflammasome (17). Inflammasomes are cytosolic multiprotein complexes containing cytoplasmic receptors of the NALP (NACHT, LRR and pyrin domain-containing protein)
family as central components (17). These inflammasomes can be activated by bacterial toxins, and by endogenous danger signals from intracellular pathogens (18; 19). Furthermore,
lysosomal damage has been shown to induce NALP3 activation (20).
Using a peptide such as acALY-18, which was originally derived and identified from the
naturally occurring TRPC1 protein (13), to induce the innate immune response, provides
an unique opportunity to improve processing and clearance of intracellular pathogens, such
as C. pneumoniae. Harnessing this more natural approach in combating infection may have
implications for Alzheimer’s disease therapy that incorporates a variety of environmental
factors, including infection, as major risks and/or causative agents in disease pathogenesis.

Topology of TRPC1

Innate and adaptive immunity gene
expression in C. pneumoniae infected
monocytes as compared to infected
monocytes treated with acALY-18

Alzheimer gene expression in C. pneumoniae
infected versus uninfected human THP1
monocytes

Select Alzheimer’s disease microarray genes (con’t)
Function

Gene symbol

Gene name

Protein kinases
CDC2
CDK5
GSK3A
GSK3B
PRKCB
PRKCE
PRKCI

Cell division cycle 2, G1 to S & G2 to M
Cyclin-dependent kinase 5
Glycogen synthase kinase 3 alpha
Glycogen synthase kinase 3 beta
Protein kinase C, beta
Protein kinase C, epsilon
Protein kinase C, iota

APLP2
GNB1
GNB4
GNG10
GNG11
GNG3
GNG4
GNGT2

GNB2
IL1A

β-amyloid precursor-like protein 2
G protein, β 1
G protein, β 4
G protein, γ 10
G protein, γ 11
G protein, γ 3
G protein, γ 4
G protein, γ transducing activity polypeptide 2
APBA3 Amyloid beta (A4) precursor proteinbinding, family A, member3
G protein, β 2
Interleukin 1, α

HSD17B10
UQCRC1
UQCRC2

Hydroxysteroid (17-β) dehydrogenase 10
Ubiquinol-cytochrome c reductase core protein I
Ubiquinol-cytochrome c reductase core protein II

Cell signaling molecules
G-protein coupled receptor

Other signaling molecules

Oxidoreductases & oxidative stress

Figure 1: The PDAG peptide (acALY-18) sequence is homologous with an extracellular
loop of TRPC1, a transmembrane Ca 2+ channel protein. Percent homology between
TRPC1 and other members of the TRP family is indicated. A putative pore loop is indicated between transmembrane segments S5 and S6. The region indicated by the red circle
is the pDAG peptide sequence. Arrowheads indicate small gaps present in homology of
TRPC1 relative to other TRP family members.

Conclusions

Synthetic PDAG peptide
(acALY-18) decreases infection
in monocytes
A

Figure 3: Fold regulation of expression in a subset of genes in Chlamydia pneumoniae AR-39
infected cells (MOI =1) relative to PDAG peptide (acALY-18) treated cells at 48hr postinfection. Data for infected cells were derived from 4 sets of experiments. Data for acALY-18
treated infected cells were derived from 2 experiments. Genes were detected using an innate
and adaptive immunity RT 2PCR array from SABiosciences (Qiagen) *p < .05, **p > .05 and < 0.1
relative to uninfected THP1 monocyte gene expression.

Figure 4: Fold regulation of expression in a subset of genes in Chlamydia pneumoniae
AR-39 infected cells (MOI =1) relative to uninfected cells. Data were derived from 4
sets of experiments. Genes were detected using an Alzheimer's disease RT2PCR array
from SABiosciences (Qiagen) *p < .05, **p > .05 and < 0.1.

Select innate and adaptive immunity microarray genes
Function

Gene symbol

Gene name

Select Alzheimer’s disease microarray genes

Inflammatory response
IL1A
IL1B
IL1F10
IL1F5
IL1F8
IL1R1
IL1RN
IRAK2
MYD88
TLR1
TLR10
TLR6
TLR8
TNF

Interleukin 1, alpha
Interleukin 1, beta
Interleukin 1 family, member 10 (theta)
Interleukin 1 family, member 5 (delta)
Interleukin 1 family, member 8 (eta)
Interleukin 1 receptor, type I
Interleukin 1 receptor antagonist
Interleukin-1 receptor-associated kinase 2
Myeloid differentiation primary response gene (88)
Toll-like receptor 1
Toll-like receptor 10
Toll-like receptor 6
Toll-like receptor 8
Tumor necrosis factor (TNF superfamily, member 2)

Host defense against bacteria
CAMP
DEFB4
DMBT1
IRF1
NCF4
NFKBIA

Figure 2: Percent cells infected with Chlamydia pneumoniae (A) as determined by counting
infected cells (green labeling) in THP1 monolayers untreated (B) or treated (C) with
acALY-18 peptide at 24hrs post-infection and processed at 48hrs post-infection.

C. pneumoniae infection of human monocytes alters gene expression for markers of the innate and adaptive immune response
❍ Altered gene expression prevents adequate clearance of the organism
from the professional killing cells thereby promoting persistent infection.
❍ Ineffective clearance of infection maintains chronic turn-on of an
inflammatory response by infected monocytes as reflected by specific
gene expression
● C. pneumoniae infection of human monocytes alters gene expression for markers of Alzheimer’s disease
❍ Increased expression of specific genes demonstrates the effect of intracellular infection on genes associated with all aspects of
cellular function
❍ These data support our contention that C. pneumoniae infection is a
“trigger” for altered gene expression in the pathogenesis of Alzheimer’s
disease
● The novel PDAG peptide acALY-18 induces expression of genes
associated with innate and adaptive immunity to effectively reduce
C. pneumoniae infection of monocytes
❍ acALY-18 may be a viable candidate for treating this infection in
Alzheimer’s disease.
●

S100A12
Cytokines, chemokines & their receptors
CCL2
CXCR4
IFNA1
IFNB1
IFNGR1
IL1F7
IL1F9
IL6
Antibacterial humoral response
COLEC12
CYBB
LY96
Septic shock
Apoptosis associated with ADORA2A
septic shock
IL10
PROC
Other genes involved in
HMOX1
septic shock
SERPINA1
SERPINE1
TREM1

Cathelicidin antimicrobial peptide
Defensin, beta 4
Deleted in malignant brain tumors 1
Interferon regulatory factor 1
Neutrophil cytosolic factor 4, 40kDa
Nuclear factor of kappa light polypeptide gene enhancer in Bcells inhibitor, alpha
S100 calcium binding protein A12

Function
Secretases

Other peptidases
β-amyloid clearance through
endocytosis
Other genes involved in
β-amyloidmetabolism

Gene name

ADAM9
APH1A
BACE2
CTSB
PSEN1
IDE
PLAU
APLP1
APP
LRP6
A2M
APBB1
UBQLN1

ADAM metallopeptidase domain 9
Anterior pharynx defective 1 homolog A (C. elegans)
β-site APP-cleaving enzyme 2
Cathepsin B
Presenilin 1
Insulin-degrading enzyme
Plasminogen activator, urokinase
β-amyloid precursor-like protein 1
β-amyloid precursor protein
LDL receptor-related protein 6
α-2-macroglobulin
β-amyloid precursor protein-binding, family B, member 1
Ubiquilin 1

ACHE
APBA1

Lipid, lipoprotein & cholesterol

Collectin sub-family member 12
Cytochrome b-245, beta polypeptide
Lymphocyte antigen 96

Apoptosis
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Synaptic formation

Chemokine (C-C motif ) ligand 2
Chemokine (C-X-C motif ) receptor 4
Interferon, alpha 1
Interferon, beta 1, fibroblast
Interferon gamma receptor 1
Interleukin 1 family, member 7 (zeta)
Interleukin 1 family, member 9
Interleukin 6 (interferon, beta 2)

Adenosine A2a receptor
Interleukin 10
Protein C (inactivator of coagulation factors Va and VIIIa)
Heme oxygenase (decycling) 1
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antit
rypsin), member 1
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator
inhibitor type 1), member 1
Triggering receptor expressed on myeloid cells 1

Gene symbol

β-amyloid processing & clearance

CHAT

Acetylcholinesterase (YT blood group)
Amyloid beta (A4) precursor protein-binding, family A,
member1
Choline acetyltransferase

ABCA1
APOA1
APOE
CLU
LRP1
LRP8

ATP-binding cassette, sub-family A (ABC1), member 1
Apolipoprotein A-I
Apolipoprotein E
Clusterin
LDL-related protein 1 (α-2-macroglobulin receptor)
LDL receptor-related protein 8 (apolipoprotein e receptor)

CASP3
CASP4
EP300

Caspase 3, apoptosis-related cysteine peptidase
Caspase 4, apoptosis-related cysteine peptidase
E1A binding protein p300

CTSC
CTSD
CTSL

Cathepsin C
Cathepsin D
Cathepsin L1

metabolism

Proteases
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